Life Science Investing Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
Life Science Investing Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update
Life Science Investing Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025
Life Science Investing Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting
Life Science Investing Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses
Life Science Investing Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary
Homerun Resources Inc. Receives Conditional Approval from the TSXV for $6 Million Financing with Institutional Investor
Silver Dollar Samples Up to 2,753 g/t AgEq in Underground Sampling Campaign at its La Joya Silver Project
